Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial.
about
Cytotoxic and targeted therapy for hereditary cancersUpdate on Imaging of Ovarian CancerSelecting the best strategy of treatment in newly diagnosed advanced-stage ovarian cancer patientsMajor clinical research advances in gynecologic cancer in 2015Mesothelium expression of vascular cell adhesion molecule-1 (VCAM-1) is associated with an unfavorable prognosis in epithelial ovarian cancer (EOC).Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center.Dose-dense paclitaxel plus carboplatin as neoadjuvant chemotherapy for advanced ovarian, fallopian tube, or primary peritoneal carcinomas.Major clinical research advances in gynecologic cancer in 2016: 10-year special edition.Factors Predicting Use of Neoadjuvant Chemotherapy Compared With Primary Debulking Surgery in Advanced Stage Ovarian Cancer-A National Cancer Database Study.Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline.Distinct implications of different BRCA mutations: efficacy of cytotoxic chemotherapy, PARP inhibition and clinical outcome in ovarian cancerSurvival outcomes after extensive cytoreductive surgery and selective neoadjuvant chemotherapy according to institutional criteria in bulky stage IIIC and IV epithelial ovarian cancer.Prediction model for 30-day morbidity after gynecological malignancy surgeryUse and Effectiveness of Neoadjuvant Chemotherapy for Treatment of Ovarian Cancer.Oncolytic Adenovirus-Loaded Menstrual Blood Stem Cells Overcome the Blockade of Viral Activity Exerted by Ovarian Cancer AscitesHepatic resection during cytoreductive surgery for primary or recurrent epithelial ovarian cancer.Intraperitoneal cisplatin and doxorubicin as maintenance chemotherapy for unresectable ovarian cancer: a case report.Surgical treatment pattern and outcomes in epithelial ovarian cancer patients from a cancer institute in Kerala, India.Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer: Where Do We Go From Here?Advanced Ovarian Cancer: Primary or Interval Debulking? Five Categories of Patients in View of the Results of Randomized Trials and Tumor Biology: Primary Debulking Surgery and Interval Debulking Surgery for Advanced Ovarian CancerSurvival and Toxicity After Cisplatin Plus Etoposide Versus Carboplatin Plus Etoposide for Extensive-Stage Small-Cell Lung Cancer in Elderly Patients.Effect of neoadjuvant chemotherapy on platinum resistance in stage IIIC and IV epithelial ovarian cancer.Neoadjuvant chemotherapy for Patients with advanced epithelial ovarian cancer: A Meta-Analysis.Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer.SEOM Clinical Guideline in ovarian cancer (2016)Recent Advances in Understanding, Diagnosing, and Treating Ovarian Cancer.The role of neoadjuvant chemotherapy in the management of patients with advanced stage ovarian cancer: Survey results from members of the society of gynecologic oncologists, a 5-year follow-up.Radiotherapy and locally advanced rectal cancer.Implementation of Extensive Cytoreduction Resulted in Improved Survival Outcomes for Patients with Newly Diagnosed Advanced-Stage Ovarian, Tubal, and Peritoneal Cancers.Frontline treatment of epithelial ovarian cancer.Appropriate Recommendations for Surgical Debulking in Stage IV Ovarian Cancer.Hyperthermic intraperitoneal chemoperfusion as a component of multimodality therapy for ovarian and primary peritoneal cancer.ABCF2, an Nrf2 target gene, contributes to cisplatin resistance in ovarian cancer cells.Prognostic value of miliary versus non-miliary sub-staging in advanced ovarian cancer.VEGF gene polymorphisms and outcome of epithelial ovarian cancer patients.Variation in neoadjuvant chemotherapy utilization for epithelial ovarian cancer at high volume hospitals in the United States and associated survival.Maximal effort cytoreductive surgery for disseminated ovarian cancer in a UK setting: challenges and possibilities.Improving outcomes for older women with gynaecological malignancies.Trends in Mortality After Primary Cytoreductive Surgery for Ovarian Cancer: A Systematic Review and Metaregression of Randomized Clinical Trials and Observational Studies.The impact of ultra-radical surgery in the management of patients with stage IIIC and IV epithelial ovarian, fallopian tube, and peritoneal cancer.
P2860
Q26739366-E11B6F8B-3082-42D5-A08D-C814D8584933Q26750610-39DE8822-4830-4654-A2C3-B5F4ACF2BA14Q26771731-EC4549B8-3186-4996-AAEF-77F238EE3A45Q28077183-06C1282F-A4D3-4612-A84F-F92F1B130493Q30253028-AD48C1F6-79B3-4100-9E80-A7F37113FF08Q30717971-90758186-7DC3-41DD-A6F6-C828F87D1E21Q33436678-3BB086B7-F766-4651-BF19-6596C28199CCQ33563963-2F4858CD-02C7-4B3B-872A-AA6C348DBE0EQ33605208-4EBB29F8-EA84-4580-AC13-4365E3A8567FQ33626973-43566C14-4207-489D-8E92-C18C5F7A766AQ33704050-41771929-FCCF-4F77-9A43-889D7E28C434Q33735142-19B56559-03E2-4F02-9041-7BF96C3582F3Q33751884-018E082C-7EFE-426D-BAFD-9D6B0CEDAED7Q33816983-6F259BBC-581D-41D8-AE2C-E8AD2C44BF1FQ33904378-B97EBCDC-9CB3-43E1-97A5-2BAE6DC585E1Q35867496-6033D21D-0B86-4D88-8E8D-C65D4E0E1352Q36243127-3BB94658-1E42-429B-88A8-408D55781FF4Q36581627-36414038-ADA3-4F10-8F10-760E3DC6557DQ36884415-7E96FB34-7E2D-4B3C-9C4E-794DC2A80F51Q37017000-B4F2DE59-4842-48FB-98FD-A925C071FC06Q37117864-D697CF15-9FC4-4719-B697-D8061E385666Q37257019-CCE72C79-58AD-40B6-A780-4287450EFB0DQ37386124-6A635AEB-A1A7-4AA2-8CBC-66861D7259B1Q37466140-B4EB7438-85BE-40E0-9B8A-B0DCD231E64CQ37475168-E6CE5AE0-0335-4B91-A0F1-2F5D127DBC7AQ37620476-83BEB7B6-6335-4DEE-AE82-26B2ED6CBBBAQ37691445-1A3B3BC1-D651-4230-9318-305C48AFC9EBQ38604995-160C087C-B2A8-4787-A57D-A44F08D2674BQ38631105-CFD1395C-266A-4ABA-9FF3-D0DFFDDB0230Q38669746-227D6130-CD3D-4214-80BC-A14AB9B0EADBQ38682323-C1A8E189-C2EF-4134-AFEF-27489C90C1BFQ38719149-0AB62C54-5CD5-40D7-8578-0772EB40686DQ38719990-96F6DEF0-5FC1-42E9-B4C2-CA3DD7D63A81Q38791320-7141EA07-18C5-4794-AB10-4B5B3369D322Q38805626-C33F009B-1621-40EC-9DDF-1B099E21336DQ38861953-7CAA92A7-D3BC-48A9-B5E2-8F2BC5E2F683Q38886537-28B7B711-ADDB-4362-9433-69904FCCC970Q38963512-2B7F8792-F8C4-407B-9F46-D00AB415438CQ39023165-3D8DEF02-600C-4751-BDCB-C68C78DAE2F9Q39084944-52A5B495-D275-4463-996D-245447F42B3A
P2860
Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Primary chemotherapy versus pr ...... rolled, non-inferiority trial.
@en
type
label
Primary chemotherapy versus pr ...... rolled, non-inferiority trial.
@en
prefLabel
Primary chemotherapy versus pr ...... rolled, non-inferiority trial.
@en
P2093
P50
P1433
P1476
Primary chemotherapy versus pr ...... trolled, non-inferiority trial
@en
P2093
Ann-Marie Swart
David Luesley
Glenn McCluggage
Henry Kitchener
Jeremy Twigg
Jonathan Herod
Mahesh Parmar
Matthew Nankivell
Sean Kehoe
P304
P356
10.1016/S0140-6736(14)62223-6
P407
P577
2015-05-19T00:00:00Z